- Home
- ANVS vs VERU Comparison
ANVS vs VERU Comparison
Compare ANVS & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- VERU
- Stock Information
- Founded
- ANVS 2008
- VERU 1971
- Country
- ANVS United States
- VERU United States
- Employees
- ANVS N/A
- VERU N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- VERU Health Care
- Exchange
- ANVS Nasdaq
- VERU Nasdaq
- Market Cap
- ANVS 53.3M
- VERU 54.6M
- IPO Year
- ANVS 2020
- VERU 1990
- Fundamental
- Price
- ANVS $3.69
- VERU $2.53
- Analyst Decision
- ANVS Strong Buy
- VERU Strong Buy
- Analyst Count
- ANVS 3
- VERU 2
- Target Price
- ANVS $13.50
- VERU $25.00
- AVG Volume (30 Days)
- ANVS 3.0M
- VERU 189.8K
- Earning Date
- ANVS 11-12-2025
- VERU 12-15-2025
- Dividend Yield
- ANVS N/A
- VERU N/A
- EPS Growth
- ANVS N/A
- VERU N/A
- EPS
- ANVS N/A
- VERU N/A
- Revenue
- ANVS N/A
- VERU $16,886,419.00
- Revenue This Year
- ANVS N/A
- VERU N/A
- Revenue Next Year
- ANVS N/A
- VERU N/A
- P/E Ratio
- ANVS N/A
- VERU N/A
- Revenue Growth
- ANVS N/A
- VERU 337.24
- 52 Week Low
- ANVS $1.11
- VERU $2.42
- 52 Week High
- ANVS $7.52
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- ANVS 77.19
- VERU 31.55
- Support Level
- ANVS $2.11
- VERU $2.50
- Resistance Level
- ANVS $4.00
- VERU $2.86
- Average True Range (ATR)
- ANVS 0.35
- VERU 0.19
- MACD
- ANVS 0.15
- VERU -0.01
- Stochastic Oscillator
- ANVS 70.34
- VERU 16.04
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.